SharePoint
A- A A+

For Patients & Visitors

Find a Doctor

Find a Doctor

Dr Raghav Sundar

Photo of Dr Raghav Sundar
Credential:
MBBS(S'pore), MRCP(UK), MMed(Int Med), MCI, FAMS (Oncology)
Designation:
Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
Assistant Professor

Assistant Professor, Yong Loo Lin School of Medicine, National University Singapore (NUS)

Assistant Professor, N.1 The Institute for Health, National University Singapore (NUS
Specialty:
Cancer
Sub Specialty:
Medical Oncology
Medical and Surgical Conditions:
Bile Duct Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Gastric Cancer (Stomach Cancer), Gastrointestinal Stromal Tumour (GIST), Liver Cancer, Pancreatic Cancer
Special Interest:
Gastrointestinal Cancer                                                                                              Immunotherapy                                                                                                                     Early Phase Drug Development                                                                                  Epigenetics
Biomarker development
DNA damage repair                                              
Chemotherapy-induced neuropathy
Institution:
National University Hospital
National University Cancer Institute, Singapore
National University Health System

Dr Raghav Sundar obtained his medical degree from the Yong Loo Lin School of Medicine, National University of Singapore, where his academic distinctions earned him a place in the Dean’s List and the Thambipillai Silver Medal. He topped the country in the Internal Medicine specialty examination obtaining the Master of Medicine (Internal Medicine) and the Gordon Arthur Ransome Gold Medal in Internal Medicine. He was Chief Resident and Chief Senior Resident during his training at the National University Hospital. He subsequently completed his Medical Oncology Senior Residency at the National University Cancer Institute, Singapore (NCIS). His clinical interest is in gastrointestinal cancers. His research interest lies in early phase drug development, immunotherapy, epigenetics, biomarker discovery, DNA damage repair, and chemotherapy-induced neuropathy. He was awarded the National Medical Research Council Overseas Fellowship Award to undergo fellowship training at the Drug Development Unit, Royal Marsden Hospital, UK. He won the Conquer Cancer Foundation of ASCO Merit Award for his work on developing novel anticancer therapeutics. He holds several grants and has secured over $1,500,000 in grant funding. He has published in high impact peer-reviewed journals including Cancer Discovery, Annals of Oncology and Clinical Cancer Research and designs clinical trials for novel cancer drugs. 


Leadership Positions
Chief Resident – University Medical Centre, National University Health System
Chief Resident (Academic) - University Medical Centre, National University Health System
Chief Senior Resident – Department of Haematology-Oncology, National University Health System

Awards and Honours

Conquer Cancer Foundation of ASCO Merit Award
National Medical Research Council Fellowship Award
Gordon A Ransom Gold Medal
Thambipillai Silver Medal
Dean’s List, School of Medicine, National University of Singapore
Singapore Airlines Youth Scholarship

Research and Publications

  1. Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer. Sundar R, Huang KK, Qamra A, Kim KM, Kim ST, Kang WK, Tan ALK, Lee J, Tan P. Ann Oncol. 2019 Mar 1;30(3):424-430. 
  2. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK,Sundar R, Chan A, Ng TR, Suen LKP, Chan CW, Yorke J, Lopez V. Brain Behav. 2019 May 7:e01312.
  3. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Yeo F, Ng CC, …., Lopez V, Sundar R*, Chan A. Support Care Cancer. 2019 Apr 10. * Joint corresponding authors
  4. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT, Li YC, Wong KH, Suen LKP, Chan CW, Yorke J, Farrell C, Sundar R. BMC Cancer. 2019 Feb 8;19(1):132.
  5. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Shimomura A, Yamamoto N …. Sundar R, Ohkubo S, Calleja EM, Nishio M. Mol Cancer Ther. 2019 Mar;18(3):531-540.
  6. A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. Ingles Garces AH, Ang JE … Sundar R, de Bono J, Lopez J, Banerji U. Eur J Cancer. 2018 Oct 10; 104:32-38.
  7. Real-time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept '3G' Trial. Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR,Sundar R, et al. Clin Cancer Res. 2018 Nov 1;24(21):5272-5281.
  8. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Sundar R, Miranda S, Rodrigues DN, et al. Clin Colorectal Cancer. 2018 Dec;17(4):280-284.
  9. Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. Sundar R, McVeigh T, Dolling D, et al. Eur J Cancer. 2018 Jul 16;101:55-61. 
  10. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. Basu B*, Krebs MG*, Sundar R*, et al. Ann Oncol. 2018 Sep 1;29(9):1918-1925. *Joint first authors
  11. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Sundar R, Qamra A, Tan ALK, et al. Gastric Cancer. 2018 Nov;21(6):1064-1070.
  12. Biomarkers for Homologous Recombination Deficiency in Cancer. Hoppe MM*, Sundar R*, Tan DSP, Jeyasekharan AD. J Natl Cancer Inst. 2018 Jul 1;110(7):704-713. *Joint first authors
  13. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. McVeigh TP*, Sundar R*, Diamantis N, et al. Eur J Cancer. 2018, Mar 31;95:20-29. *Joint first authors
  14. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. Sundar R, Rha SY, Yamaue H, et al. BMC Cancer. 2018 Mar 27;18(1):332.
  15. Resisting resistance to cancer immunotherapy. Lam WS, Wang LZ, … Sundar R. Thorac Cancer.2018 May;9(5):507-508.
  16. Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards? Sundar R, Tan P. Cancer Discov. 2018 Jan;8(1):14-16.
  17. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Brown JS, Sundar R, Lopez J. Br J Cancer. 2018 Feb 6;118(3):312-324.
  18. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.Sundar R, Custodio A, Petruckevitch A, et al. Clinical Oncology. 2018 Mar;30(3):185-191.
  19. Targeting BRAF Mutant Colorectal Cancer: Progress in Combination Strategies. Sundar R, Hong DS, Kopetz S, Yap T. Cancer Discov. 2017 Jun;7(6):558-560
  20. Targeting ATR in cancer medicine. Sundar R, Brown J, Ingles Russo A, Yap TA. Curr Probl Cancer. 2017 Jul - Aug;41(4):302-315.
  21. Combining molecularly targeted agents: is more always better? Sundar R, Valeri N, Harrington K, Yap T. Clin Cancer Res. 2017 Mar 1;23(5):1123-1125.
  22. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Sundar R, Chénard-Poirier M, Collins DC, Yap TA. Front Med (Lausanne). 2017 Apr 10;4:39.
  23. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Dolly SO, Collins DC, Sundar R, Popat S, Yap TA. Drugs. 2017 May;77(8):813-827.
  24. Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study. Sundar R, Bandla A, Tan SSH, et al. Front. Oncol. 2017 Jan 10;6:274.
  25. Emerging biomarkers for PD-1 pathway cancer therapy. Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA. Biomarkers in Medicine. 2017 Jan;11(1):53-67.
  26. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Collins DC, Sundar R, Lim JS, Yap TA. Trends Pharmacol Sci. 2017 Jan;38(1):25-40.
  27. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.Sundar R, Jeyasekharan AD, Pang B, Soong RCT, Kumarakulasinghe NB, et al. PLoS ONE. 2016 Oct 7;11(10):e0164319.
  28. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Wong A, Sundar R, Lee SC et al. OncoTarget 2016 Sep 27;7(39):64089-64099.
  29. Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. Sundar R, Tan D, Lim  SL, Chia WK. Current Cancer Therapy Reviews, 12(1): 23-36.
  30. Hypothermia for Preventing Chemotherapy-Induced Neuropathy – A Pilot Study on Safety and Tolerability in Healthy Controls. Bandla A, Sundar R, Wilder-Smith EP et al. Acta Oncologica2016;55(4):430-6
  31. Zinner Syndrome. Sundar R, Sundar G. BMJ Case Reports. 2015 Mar 6;2015.
  32. Nivolumab in NSCLC: latest evidence and clinical potential. Sundar R, Cho BC, Brahmer JR, Soo RA. Ther Adv Med Oncol. 2015 Mar; 7(2): 85–96.
  33. Immunotherapy in the treatment of non-small cell lung cancer. Sundar R, Soong R, Cho BC, Brahmer  JR, Soo RA. Lung Cancer. 2014 Aug;85(2):101-9.

Contact

Appt Tel:
Fax:
+65 6777 4413